Crossmark

Comparison of circulating fibrocytes from non-asthmatic patients with seasonal allergic rhinitis between in and out of pollen season samples

Crossref DOI link: https://doi.org/10.1186/s13223-022-00663-5

Published Online: 2022-03-16

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Côté, Marie-Ève

Boulay, Marie-Ève

Plante, Sophie

Côté, Andréanne

Chakir, Jamila

Boulet, Louis-Philippe https://orcid.org/0000-0003-3485-9393
License Information

Text and Data Mining valid from 2022-03-16

Version of Record valid from 2022-03-16
More Information

Article History

Received: 27 October 2021

Accepted: 20 February 2022

First Online: 16 March 2022

Declarations

:

: The study was approved by the IUCPQ-UL ethics committee (CÉR 21109).

: Not applicable.

: MEC, MEB, SP, and JC have no competing interests to declare. AC considers having no conflicts of interest related to this study, but wishes to declare what can be perceived as potential conflicts of interest. Research grants for participation to multicentre studies: AstraZeneca. Fee for consulting and advisory boards: AstraZeneca, Sanofi. LPB considers having no conflicts of interest related to this study, but wishes to declare what can be perceived as potential conflicts of interest. Research grants for participation to multicentre studies: AstraZeneca, Boston Scientific, GlaxoSmithKline, Hoffman La Roche, Novartis, Ono Pharma, Sanofi, Takeda. Support for research projects introduced by the investigator: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Takeda. Fee for consulting and advisory boards: AstraZeneca, Novartis, Methapharm. Nonprofit grants for production of educational materials: AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis. Conference fees: AstraZeneca, GlaxoSmithKline, Merck, Novartis.

Document is current

Any future updates will be listed below